Immuneering (IMRX) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Immuneering (IMRX) has outperformed Rocket Pharmaceuticals (RCKT) over the past year, losing 35.7% versus a loss of 41.2%. Over five years, IMRX leads with a -86.1% price change compared with -92.6% for RCKT. Rocket Pharmaceuticals is the larger company by market cap ($239.3 million vs $232.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMRX | RCKT |
|---|---|---|
| Share price | $3.59 | $2.18 |
| Market cap | $232.26M | $239.31M |
| 1-day change | -1.37% | -7.63% |
| YTD return | -45.44% | -37.89% |
| 1-year return | -35.66% | -41.24% |
| 5-year return | -86.11% | -92.58% |
| EPS (TTM) | $-0.93 | $-0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-56.02M | $-223.12M |
| 52-week high | $8.48 | $5.45 |
| 52-week low | $3.38 | $2.17 |
| Distance from 52-week high | -57.67% | -60.00% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +378.27% | +293.58% |
| Average volume | 694.16K | 1.77M |
| Shares outstanding | 64.70M | 109.77M |
| Employees | 57 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
IMRX vs RCKT FAQ
Which is bigger, Immuneering or Rocket Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) is larger, with a market capitalization of $239.31M compared with $232.26M for Immuneering (IMRX).
Which stock has performed better over the past year, IMRX or RCKT?
IMRX returned -35.66% over the past 12 months, compared with -41.24% for RCKT (price return, excluding dividends). Past performance does not predict future results.
Are Immuneering and Rocket Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.